FDA launches pilot program to speed early-phase drug trials

The U.S. Food and Drug Administration announced a new pilot program aimed at accelerating the review of Phase 1 clinical trials for investigational new drugs.

The initiative introduces a rolling submission process, letting sponsors submit data incrementally instead of waiting for a complete package.

Sponsors will be paired with qualified research institutions to help streamline the expedited review, the agency said.